
Background Quantitative complement assessment, alongside classical pathway functional complement (CH50) testing, is essential for diagnosing complement deficiencies and complement-mediated disorders. We developed two new automated turbidimetric immunoassays, the Optilite® C1q and C2, validated their analytical performance, and evaluated their clinical utility in patients with complement-mediated renal diseases and complement deficiencies. Methods We assessed the analytical performance of the C1q and C2 immunoassays using native and surrogate patient samples according to relevant CLSI guidelines. Reference ranges were determined using samples from healthy European donors. C1q and C2 results were compared with available CH50, C3 and C4 data in C3 glomerulopathy (C3G; n = 46), atypical haemolytic uremic syndrome (aHUS; n = 18), and inherited complement deficiency (n = 23) cohorts. Results Optilite C1q and C2 immunoassays demonstrated robust analytical performance with total precision of 2.5–3.8% CV and 4.9–5.7% CV for C1q and C2, respectively. Reference ranges were 119.77–195.76 mg/L for C1q and 10.589–23.932 mg/L for C2. Assays showed strong agreement with established methods (87.3% for C1q; 95.1% for C2), and the equivalency of serum and plasma matrices was demonstrated. In patients with C3G and aHUS, C2 and C4 concentrations (and to a lesser extent C1q) were within reference limits, whereas CH50 activity and C3 concentrations were reduced. In inherited complement deficiency cohorts, C2 levels reflected the clinical diagnosis, including identification of a homozygous C2-null patient, while C1q measurements provided additional diagnostic insights. Normal CH50 activity was observed only when both C1q and C2 levels were normal or borderline. Conclusion These new C1q and C2 immunoassays are analytically robust and provide a more complete complement profile when used alongside functional and other quantitative antigen testing.
Background Phosphatidylethanol (PEth) is a sensitive biomarker of ethanol exposure; however, interpretive ambiguity persists in the 10–19 ng/mL range. Incidental exposure to ethanol-containing products may contribute to low-level PEth formation, but potential additive effects from concurrent exposure have not been systematically evaluated. This study assessed whether hand sanitizer and mouthwash, alone or in combination, influence PEth concentrations. Methods In this prospective pilot study, 42 adults were assigned to hand sanitizer (70% ethanol, 10 uses/day), mouthwash (21.6% ethanol, 4 uses/day), combined exposure (both mouthwash and hand sanitizer) or control groups for 14 days. Blood samples were collected at baseline, Day 7, and Day 14. PEth 16:0/18:1 (POPEth) was quantified by LC-MS/MS (LLOQ 10 ng/mL; LOD 0.7 ng/mL). Within-group changes were evaluated using paired, one-sided t-tests. Exposure groups were compared with controls using one-sided permutation tests, and combined exposure was compared with individual exposure groups using one-sided Welch two-sample t-tests. Results All participants had baseline POPEth concentrations below the LLOQ. No significant increases from baseline or differences from controls were observed in any exposure group (p > 0.05 for all comparisons). Combined exposure did not result in significantly higher POPEth concentrations than either individual exposure (p > 0.05). Small increases above the LOD (≤3 ng/mL) did not approach the LLOQ. No protocol-adherent participants exceeded the LLOQ. Discussion Concurrent exposure did not result in a measurable additive effect on POPEth concentrations under the conditions evaluated. Incidental exposure to these products is unlikely to meaningfully affect interpretation at established clinical decision thresholds; however, larger studies are warranted to confirm these findings.
Background The clinical value of serum folate testing has been increasingly questioned, largely based on evidence from countries with mandatory folic acid fortification where deficiency is uncommon. Whether these conclusions apply to non-fortified European populations remains uncertain. Moreover, successive modifications of the Roche Elecsys® Folate III assay may have influenced measured folate concentrations and the estimated prevalence of deficiency. Methods We retrospectively analyzed 178,323 serum folate measurements from patients tested at the San Raffaele Hospital (Milan, Italy) between January 2022 and June 2026. Monthly mean folate concentrations and the proportion of tests below the laboratory-defined decision limit (5.38 ng/mL) were evaluated in relation to successive reagent updates, including the introduction of a biotin-tolerant assay version and the subsequent manufacturer corrective action. Results Mean serum folate concentrations remained stable throughout 2022, increased during 2023, declined markedly after implementation of the updated assay, and rose again following the introduction of corrected reagent lots in 2025. The proportion of tests below the laboratory-defined decision limit increased significantly from 31.2 ± 3.3% during 2022–2023 to 42.9 ± 3.8% during 2024–2026 (P < 0.001). Although mean folate concentrations increased following implementation of the 2025 corrective action, it had little apparent effect on the proportion of results below the laboratory-defined decision limit. Conclusions Modifications of the Elecsys Folate III assay were temporally associated with substantial changes in serum folate measurements and an increase of more than 10 percentage points in the proportion of results below the laboratory-defined decision limit. These findings indicate that assay-related bias, particularly at low folate concentrations, may affect the estimates of the proportion of results below the laboratory-defined decision limit, and conclusions regarding the clinical utility and cost-effectiveness of serum folate testing. Analytical standardization should therefore be considered when interpreting serum folate data.
Introduction: Homovanillic acid (HVA) and vanillylmandelic acid (VMA) are used in diagnosis of neuroblastoma. 5-hydroxyindolacetic acid (5-HIAA) is used in diagnosis of intestinal carcinoid syndrome. The aim of this study is to optimize and verify the Chromsystems kit for these cancer biomarkers on our Waters Xevo TQ-S Cronos LC-MS/MS.Materials and Methods: The method was optimized and verified for our LC-MS/MS. The verification included simple (SP) and complex precision (CP), lower limit of detection (LLD) and quantification (LLQ), linearity, carryover, bias through measuring external quality assessment (EQA) samples, and patient comparison with another laboratory that already validated the LC-MS/MS method.Results: For two levels of HVA quality control: SP was 1.3% and 1.8%, CP 4.9% and 3.0%; VMA: SP was 1.5% and 1.3%, CP was 3.5% and 1.6%; and 5-HIAA: SP was 0.7% and 0.9%, CP was 5.4% and 3.8%. The LLD and LLQ were 0.587 μmol/L and 1.20 μmol/L, 0.138 μmol/L and 0.65 μmol/L, and 0.0464 μmol/L and 5.03 μmol/L for HVA, VMA and 5-HIAA, respectively. The linearity was 1.20 – 290.4 μmol/L (HVA), 0.64 – 910.7 μmol/L (VMA) and 5.03 – 1103.4 μmol/L (5-HIAA), without carryover for three analytes. The LC-MS/MS method had no significant bias when compared to the EQA assigned values. The patient comparison had Passing-Bablok regression equations for HVA: y = ‐0.4801 + 1.153x; VMA: y = ‐0.3784 + 1.139x; and 5-HIAA: y = 0.0749 +1.140x. The new reference intervals were adjusted for our method using the method comparison.Conclusions: We successfully optimized and verified the combination of a Chromsystems kit and laboratory developed method for measuring urinary HVA, VMA and 5-HIAA on our Waters LC-MS/MS.